OneSource Pharma Secures NSE/BSE No Objection for Steriscience Merger

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSimar Singh|Published at:
OneSource Pharma Secures NSE/BSE No Objection for Steriscience Merger
Overview

OneSource Specialty Pharma Limited has achieved a significant milestone, securing 'No Objection' or 'No Adverse Observation Letters' from both the NSE and BSE for its proposed merger scheme with Steriscience group entities. The approvals, dated February 25, 2026, allow the company to proceed towards seeking necessary sanctions from the National Company Law Tribunal (NCLT) and other authorities. This marks a crucial step in consolidating operations across multiple entities into OneSource.

OneSource Pharma Secures NSE, BSE Nod for Steriscience Group Merger

OneSource Specialty Pharma Limited announced on February 26, 2026, that it has received 'No Objection' or 'No Adverse Observation Letters' from the NSE and BSE, dated February 25, 2026, for its proposed merger scheme. These approvals are valid for six months, requiring submission to the NCLT by August 25, 2026.

Reader Takeaway: Merger advances with exchange nods; NCLT and court approvals remain key hurdles.

What just happened (today’s filing)

OneSource Specialty Pharma Limited has taken a significant step forward in its proposed amalgamation plan. The company confirmed receipt of 'No Objection' or 'No Adverse Observation Letters' from both the National Stock Exchange of India (NSE) and BSE Limited. These letters are critical regulatory clearances, greenlighting the draft scheme of arrangement and amalgamation. The approvals are subject to specific conditions and ongoing disclosure requirements stipulated by the stock exchanges and SEBI.

The scheme involves the absorption of several Steriscience group entities, including Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, and Strides Pharma Services Private Limited, into OneSource Specialty Pharma Limited. The 'No Objection' letters were issued by NSE and BSE on February 25, 2026.

Why this matters

Securing these 'No Objection' letters from the principal stock exchanges is a pivotal requirement before the company can petition the National Company Law Tribunal (NCLT) for final approval. It signifies that the exchanges have reviewed the proposed scheme and found no immediate adverse observations, paving the way for the complex integration process to proceed.

This regulatory acceptance is a crucial enabler for OneSource to consolidate its operations and achieve its strategic objectives through the amalgamation of these diverse entities, enhancing its market position. The validity of these letters, set at six months, injects urgency into the subsequent approval stages.

The backstory (grounded)

OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, was relisted on the BSE and NSE on January 24, 2025, following a prior scheme of arrangement. This latest merger initiative appears to build on earlier strategic moves. Reports from September 2025 highlighted a potential $2.7 billion acquisition deal involving Steriscience's European CDMO business and Brooks Steriscience's Indian operations, aimed at global expansion and portfolio diversification.

Steriscience Specialties Private Limited, founded in 2020, contributes its manufacturing capabilities in carbapenems and other injectables. Brooks Steriscience Limited is a joint venture formed in 2021, adding to the group's operational footprint.

What changes now

  • The company can now initiate the process of filing the scheme with the NCLT for its adjudication and approval.
  • It must adhere to the conditions and disclosure norms mandated by NSE, BSE, and SEBI throughout the approval process.
  • The amalgamation aims to consolidate specific sterile injectable and anti-infective manufacturing operations under OneSource.
  • Shareholders and creditors of all involved entities will participate in subsequent approval processes.

Risks to watch

  • The stock exchanges reserve the right to withdraw their 'no adverse observation' if any submitted information is found to be incomplete, incorrect, or misleading. [cite: input]
  • The scheme is contingent upon obtaining final approvals from the NCLT in Mumbai, the Singapore Court, and the respective shareholders and creditors of the amalgamating entities. [cite: input, 11]
  • The 'No Objection' letters are valid only for six months from February 25, 2026; failure to submit to the NCLT within this period necessitates a re-application. [cite: input]
  • SEBI and stock exchanges explicitly disclaim responsibility for the financial soundness or correctness of statements related to the scheme. [cite: input]
  • Past FDA inspections at OneSource facilities have sometimes noted issues, although recent ones have concluded with 'Voluntary Action Indicated' (VAI) status.

Peer comparison

OneSource Specialty Pharma operates in the CDMO and specialty pharma space. Key Indian peers include established players like Cipla Ltd. and Lupin Ltd., known for their broad pharmaceutical offerings. Other comparable entities in the CDMO segment include Kemwell Biopharma, which also provides biopharmaceutical services, highlighting the competitive landscape for integrated manufacturing solutions.

Context metrics (time-bound)

  • The 'No Objection / No Adverse Observation Letters' from NSE and BSE were issued on February 25, 2026.
  • The validity period for these letters is six months, meaning the scheme must be submitted to the NCLT by August 25, 2026.

What to track next

  • Submission and progress of the scheme before the National Company Law Tribunal (NCLT).
  • Obtaining necessary approvals from the Singapore Court.
  • Securing positive votes from shareholders and creditors of all involved companies.
  • Compliance with all ongoing disclosure requirements from NSE, BSE, and SEBI.
  • Management's execution timeline for completing the merger process within the stipulated validity period.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.